Table 8.8 Cancer of the Esophagus (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
F Wass Dalatina Consider] /Danasant)								
5-Year Relative Surviva Year of Diagnosis:	I (Percent)								
1960-1963 ^a		_	_	4	4	6	1	0	2
	_	- -		4	4		4	4	3
1970-1973 ^a			-			4			
1975-1977 ^b	5.0	4.0	7.5	5.5	4.8	7.0	3.5	2.0	7.7
1978-1980 ^b	5.0	4.8	5.6	5.3	5.3	5.2	4.3	3.4	6.8
1981-1983 ^b	6.6	6.0	8.2	7.3	6.5	9.0	4.3	3.7	6.5
1984-1986 ^b	9.5	8.4	12.1	10.2	9.0	13.0	8.7	8.2	9.9
1987-1989 ^b	9.5	9.4	9.7	10.5	11.0	9.4	6.6	5.3	10.2
1990-1992 ^b	12.1	11.7	13.4	12.9	12.3	14.8	9.1	9.4	8.4
1993-1995 ^b	12.1	12.2	11.6	13.4	13.6	12.7	7.6	7.8	6.9
1996-1998 ^b	13.4	13.1	14.4	14.2	14.0	14.7	10.2	8.5	13.6
1999-2001 ^b	18.1	17.7	19.6	18.8	18.6	19.8	12.8	11.1	16.3
2002-2004 ^b	18.2	17.9	19.0	19.5	19.6	19.4	11.0	8.0	16.5
2002-2004 2005-2011 ^b	20.1 ^f	20.2 ^f		21.0 ^f	21.2 ^f	20.5 ^f	13.6 ^f		15.7 ^f
2005-2011	20.1	20.2	19.8 ^f	21.0-	21.2	20.5	13.6	12.6 ^f	15./-
5-Year Period Survival	(Percent) ^{cd}								
2011	18.3	18.5	17.6	19.1	19.5	17.5	11.7	9.9	15.4
Stage Distribution (%)	2005-2011 ^{ce}								
All Stages									
Number of cases	20,668	16,257	4,411	17,206	13,802	3,404	2,279	1,569	710
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	21	20	23	21	20	23	18	17	20
Regional	31	31	29	31	31	29	32	32	33
Distant	38	39	32	38	39	31	38	40	34
Unstaged	11	10	16	11	9	17	12	11	13
Ulistaged	11	10	10	11	,	Ι,	12	11	13
5-Year Relative Surviva	l (Percent), 2	2005-2011 ^c							
Age at Diagnosis:									
Ages <45	20.7	22.3	12.2	20.9	22.8	8.5	16.0	13.3 ^g	22.2 ^g
Ages 45-54	20.7	19.9	24.6	22.8	21.3	30.4	10.6	10.8	10.2
Ages 55-64	19.6	19.1	22.4	20.8	20.5	22.6	12.6	10.1	20.6
Ages 65-74	20.1	19.9	20.8	20.7	20.6	21.2	14.3	12.9	16.4
Ages 75+	11.6	11.9	10.9	11.7	12.0	11.1	9.9	10.7	8.2
			22.5	21.4	20.9	24.3			
Ages <65	20.1	19.6					12.2	10.5	16.8
Ages 65+	15.9	16.3	14.8	16.3	16.7	14.8	12.5	11.9	13.0
Stage ^e :									
All Stages	17.9	17.9	17.7	18.6	18.8	18.0	12.2	11.0	15.1
Localized	40.4	42.2	34.2	42.2	44.1	35.4	24.5	23.3	26.5
Regional	21.6	21.7	21.4	22.5	22.5	22.8	15.2	15.5	14.2
	4.2		5.3	4.2			4.2	2.5	8.6
Distant		4.0			4.1	4.7			
Unstaged	12.0	12.1	11.7	11.6	12.3	10.0	10.7	8.8	14.3 ^g

Based on End Results data from a series of hospital registries and one population-based registry.

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2012.

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2012.

Period survival provides a 2011 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2009-2011: 0-1 year survival),

^{(2008-2010: 1-2} year survival), (2007-2009: 2-3 year survival), (2006-2008: 3-4 year survival), (2005-2007: 4-5 years survival).

Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding. The difference between 1975-1977 and 2005-2011 is statistically significant (p<.05).

The standard error is between 5 and 10 percentage points.

The standard error is greater than 10 percentage points.

Statistic could not be calculated due to fewer than 25 cases during the time period.